Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: A qualitative study of reports to a consumer association

BMC Pharmacology and Toxicology

Volumn 13, Issue , 2012, Pages

  Vilhelmsson, Andreas ^a   Svensson, Tommy ^a,b   Meeuwisse, Anna ^c   Carlsten, Anders ^d  

^a NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ADVERSE DRUG REACTION; ANXIETY; ARTICLE; BLUNTED AFFECT; CONSUMER; CONTENT ANALYSIS; DEPERSONALIZATION; DEPRESSION; DIZZINESS; DOCTOR PATIENT RELATION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; INTERNET; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; PANIC; POLYPHARMACY; QUALITATIVE RESEARCH; RECURRENCE RISK; SIDE EFFECT; SUICIDAL IDEATION; SWEDEN; TRUST; LEGAL ASPECT; METHODOLOGY; ORGANIZATION AND MANAGEMENT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIDEPRESSIVE AGENTS; CONSUMER PARTICIPATION; PHARMACOVIGILANCE; SWEDEN;

MLCS; MLOWN;

EID: 84879153006     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-13-19     Document Type: Article

References (47)

1. The EU Pharmacovogilance System [http://ec.europa.eu/health/files/eudralex/vol-1/reg_2010_1235/reg_2010_1235_en.pdf].
2. Borg J-J, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to?. Drug Saf 2011, 34(3):187-197. 10.2165/11586620-000000000-00000, 21332243.
3. World Health Organization Safety of Medicines-a Guide to Detecting and Reporting Adverse Drug. Reaction - Why Health Professionals Need to Take Action 2002, Geneva, World Health Organization.
4. World Health Organization The Safety of Medicines in Public Health Programmes: pharmacovigilance An Essential Tool 2006, Geneva, World Health Organization.
5. Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC. Evaluation of the patient reporting of adverse drug reactions to the UK 'yellow card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess 2011, 15(20).
6. van Geffen ECG, van der Wal SW, van Hulten R, de Groot MCH, Egberts ACG, Heerdink ER. Evaluation of patients' experiences with antidepressants reported by means of a medicine reporting system. Eur J Clin Pharmacol 2007, 63:1193-1199. 10.1007/s00228-007-0375-4, 2071966, 17874086.
7. Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions. A retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf 2009, 32(11):1067-1074. 10.2165/11316680-000000000-00000, 19810778.
8. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 2006, 63(2):148-156.
9. Vilhelmsson A, Svensson T, Meeuwisse A, Carlsten A. What can we learn from consumer reports on psychiatric adverse drug reactions with antidepressant medication? Experiences from reports to a consumer association. BMC Clin Pharmacol 2011, 11:16. 10.1186/1472-6904-11-16, 3215951, 22026961.
10. Egberts TCG, Smulders M, de Koning FHP, Meyboom RHB, Leufkens HGM. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 1996, 313:530-531. 10.1136/bmj.313.7056.530, 2351951, 8789980.
11. Medical Products Agency Inrapporterade Biverkningar 2011 från hälso- och sjukvården samt allmänheten [in Swedish] [http://www.lakemedelsverket.se/Alla-nyheter/NYHETER-2012/Inrapporterade-biverkningar-2011/], Medical Products Agency.
12. Patton MQ. Qualitative Research & Evaluation Methods 2002, Sage Publications, London.
13. Bowling A. Research Methods in Health. Investigating Health and Health Services 2002, Open University Press, Norfolk.
14. Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve thrustworthiness. Nurs Educ Today 2004, 24:105-112.
15. Teal J. Nothing personal: an empirical phenomenological study of the experience of "being-on-an-SSRI". J Phenomenol Psychol 2009, 40:19-50.
16. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990, 147(2):207-210.
17. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993, 3(8):186-212.
18. Möller H-J. Is there evidence for negative effects of antidepressants on suicidality in depressive patients?. Eur Arch Psychiatry Clin Neurosci 2006, 256:476-496. 10.1007/s00406-006-0689-8, 17143567.
19. The National Board of Health and Welfare Antidepressiva läkemedel vid psykisk ohälsa: studier av praxis i primärvården [in Swedish] 2006, Stockholm, [http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/9424/2006-103-2_20061032.pdf], The National Board of Health and Welfare.
20. Knudsen P, Hansen EH, Eskildsen K. Leading ordinary lives: a qualitative study of younger women's perceived functions of antidepressants. Pharm World Sci 2003, 25(4):162-167. 10.1023/A:1024897427249, 12964495.
21. Cornford CS, Hill A, Reilly J. How patients with depressive symptoms view their condition: a qualitative study. Fam Practi 2007, 24:358-364.
22. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 2008, 22(3):330-332. 10.1177/0269881107081550, 18515448.
23. Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010, 167:934-941. 10.1176/appi.ajp.2010.09060880, 20478876.
24. Haddad P. Do antidepressants have any potential to cause addiction?. J Psychopharmacol 1999, 3:300-307.
25. van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts ACG. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrubt discontinuation. Eur J Clin Pharmacol 2005, 61:303-307. 10.1007/s00228-005-0921-x, 15906018.
26. The Swedish Council on Technology Assessment in Health Care: Treatment of Depression: A Systematic Review 2004, Stockholm, The Swedish Council on Technology Assessment in Health Care:.
27. Läkemedelsbehandling av depression hos vuxna och äldre [in Swedish] [http://www.sbu.se/upload/Publikationer/Content1/1/SBU_Treatment_depression.pdf].
28. Stevenson FA, Barry CA, Britten N, Barber N, Bradley CP. Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med 2000, 50:829-840. 10.1016/S0277-9536(99)00376-7, 10695980.
29. Makoul G, Arntson P, Schofield T. Health promotion in primary care: physician-patient communication and decision making about prescription medications. Soc Sci Med 1995, 41(9):1241-1254. 10.1016/0277-9536(95)00061-B, 8545677.
30. Dolovich L, Nair K, Sellors C, Lohfeld L, Lee A, Levine M. Do patients' expectations influence their use of medications?. Can Fam Physician 2008, 54:384-393. 2278356, 18337533.
31. Taylor SE. Health Psychology 2006, McGraw-Hill Education, Boston.
32. Brannon L, Feist J. Health Psychology: An Introduction to Behavior and Health 2004, Wadsworth/Thomson Learning, Belmont.
33. van Geffen EC, van Hulten R, Bouvry ML, Egberts AC, Heerdink ER. Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment. Ann Pharmacother 2008, 42(2):218-225. 10.1345/aph.1K516, 18094342.
34. Butt TF, Cox AR, Lewis H, Ferner RE. Patient experiences of serious adverse drug reactions and their attitudes to medicines. Drug Saf 2011, 34(4):319-328. 10.2165/11588460-000000000-00000, 21417504.
35. Cox AR, Butt TF. Adverse drug reactions: when the risk becomes a reality for patients. Drug Saf 2012, 35(11):977-981.
36. Haw C, Stubbs J. Patient information leaflets for antidepressants: are patients getting the information they need?. J Affect Disord 2011, 128:165-170. 10.1016/j.jad.2010.06.034, 20656359.
37. Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008, 65(4):573-579. 10.1111/j.1365-2125.2007.03064.x, 2291376, 18070216.
38. Britten N. Patients' Demands for prescriptions in primary care. BMJ 1995, 310:1084-1085. 10.1136/bmj.310.6987.1084, 2549493, 7742665.
39. Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ 2010, 340:752-756.
40. Krska J, Anderson C, Murphy E, Avery AJ, on behalf of the Yellow Card Study Collaboration How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK yellow card scheme. Drug Saf 2011, 34(5):429-436. 10.2165/11589320-000000000-00000, 21513365, on behalf of the Yellow Card Study Collaboration.
41. Anderson A, Krska J, Murphy E, Avery A, on behalf of the Yellow Card Study Collaboration The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol 2011, 72(5):806-822. 10.1111/j.1365-2125.2011.03990.x, 3243015, 21496066, on behalf of the Yellow Card Study Collaboration.
42. Ha JF, Anat DS, Longnecker N. Doctor-patient communication: a review. Ochsner J 2010, 10:38-43. 3096184, 21603354.
43. Lexchin J. Is there still a role for spontaneous reporting of adverse drug reactions?. CMAJ 2006, 174(2):191-192. 10.1503/cmaj.050971, 1329459, 16415466.
44. Herxheimer A, Crombag M-R, Alves TL. Direct Patient Reporting of Adverse Drug Reactions. A Twelve-Country Survey & Literature Review 2010, Health Action International (HAI) (Europe), Amsterdam.
45. Kessing LV, Hansen HV, Demyttenaere K, Bech P. Depressive and bipolar disorders: patients' attitudes and beliefs towards depression and antidepressants. Psychol Med 2005, 35:1205-1213. 10.1017/S0033291705004605, 16116946.
46. Zopf Y, Rabe C, Neubert A, Gaßmann KG, Rascher W, Hahn EG, Brune K, Dormann H. Women encounter ADRs more often than do men. Eur J Clin Pharmacol 2008, 64:999-1004. 10.1007/s00228-008-0494-6, 18604529.
47. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol 2010, 10:16. 10.1186/1472-6904-10-16, 3014875, 21122160.